Clinical course and prediction of survival in idiopathic pulmonary fibrosis
- PMID: 20935110
- DOI: 10.1164/rccm.201006-0894CI
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive, life-threatening, interstitial lung disease of unknown etiology. The median survival of patients with IPF is only 2 to 3 years, yet some patients live much longer. Respiratory failure resulting from disease progression is the most frequent cause of death. To date we have limited information as to predictors of mortality in patients with IPF, and research in this area has failed to yield prediction models that can be reliably used in clinical practice to predict individual risk of mortality. The goal of this concise clinical review is to examine and summarize the current data on the clinical course, individual predictors of survival, and proposed clinical prediction models in IPF. Finally, we will discuss challenges and future directions related to predicting survival in IPF.
Similar articles
-
A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.Dan Med J. 2015 Apr;62(4):B5069. Dan Med J. 2015. PMID: 25872544 Review.
-
Natural history of idiopathic pulmonary fibrosis.Respir Med. 2015 Jun;109(6):661-70. doi: 10.1016/j.rmed.2015.02.002. Epub 2015 Feb 14. Respir Med. 2015. PMID: 25727856 Review.
-
Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP).BMC Pulm Med. 2019 Apr 11;19(1):75. doi: 10.1186/s12890-019-0830-x. BMC Pulm Med. 2019. PMID: 30971235 Free PMC article.
-
Myositis-associated usual interstitial pneumonia has a better survival than idiopathic pulmonary fibrosis.Rheumatology (Oxford). 2017 Mar 1;56(3):384-389. doi: 10.1093/rheumatology/kew426. Rheumatology (Oxford). 2017. PMID: 28082622
-
Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis.Am J Respir Crit Care Med. 2016 Sep 15;194(6):711-8. doi: 10.1164/rccm.201508-1546OC. Am J Respir Crit Care Med. 2016. PMID: 26938706 Free PMC article. Clinical Trial.
Cited by
-
Clinical relevance of plasma prostaglandin F2α metabolite concentrations in patients with idiopathic pulmonary fibrosis.PLoS One. 2013 Jun 11;8(6):e66017. doi: 10.1371/journal.pone.0066017. Print 2013. PLoS One. 2013. PMID: 23776595 Free PMC article.
-
Protective effect of methotrexate on lung function and mortality in rheumatoid arthritis-related interstitial lung disease: a retrospective cohort study.Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221135314. doi: 10.1177/17534666221135314. Ther Adv Respir Dis. 2022. PMID: 36346076 Free PMC article.
-
Nurse-Led Palliative Care Clinical Trial Improves Knowledge and Preparedness in Caregivers of Patients with Idiopathic Pulmonary Fibrosis.Ann Am Thorac Soc. 2021 Nov;18(11):1811-1821. doi: 10.1513/AnnalsATS.202012-1494OC. Ann Am Thorac Soc. 2021. PMID: 34003726 Free PMC article. Clinical Trial.
-
Quantification of lung fibrosis and emphysema in mice using automated micro-computed tomography.PLoS One. 2012;7(8):e43123. doi: 10.1371/journal.pone.0043123. Epub 2012 Aug 13. PLoS One. 2012. PMID: 22912805 Free PMC article.
-
A cohort study of mortality predictors in patients with acute exacerbation of chronic fibrosing interstitial pneumonia.BMJ Open. 2013 Jul 31;3(7):e002971. doi: 10.1136/bmjopen-2013-002971. BMJ Open. 2013. PMID: 23903809 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical